{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T01:21:32Z","timestamp":1783560092283,"version":"3.55.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Dublin, Trinity College"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflamm. Res."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Inflammatory arthritis (IA) is a group of autoimmune diseases characterised by joint inflammation and progressive damage, thus impairing the patient\u2019s quality of life. The JAK\/STAT pathway inhibitor Tofacitinib has been successfully introduced into the clinic to treat patients with IA, however its direct effect on T cell responses is widely unknown. This study aims to assess the effect of Tofacitinib on T cell activation, polyfunctionality, proliferation and metabolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The effect of Tofacitinib on T cells from peripheral blood, synovial fluid and synovial tissue was evaluated with multidimensional flow cytometric analysis. T cell proliferation was assessed by flow cytometry and T cell metabolism was examined by qPCR and Seahorse XF analyser. To investigate the effect of Tofacitinib on T cell polarisation, na\u00efve T cells were differentiated into Th1, Th2 and Th17 with specific cytokine cocktails. Soluble mediators were evaluated by MSD multiplex analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Tofacitinib significantly inhibited T helper cell activation as evidenced by a marked reduction in the frequency of PD-1\/CD69\/CD25-positive cells (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.01). Reduced activation was consistent with impairment of pathogenic polyfunctionality of peripheral blood and synovial tissue-derived T cells. The impact of Tofacitinib on T cell plasticity was further substantiated by reduced T cell polarisation towards Th1 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), Th2 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05), Th17 (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05) and a reduction in genes associated with T cell functions. The attenuation of pathogenic T cell responses is linked to metabolic adaptation, with Tofacitinib leading to a switch in metabolic capacity, mainly ascribed to the CD4\n                      <jats:sup>\u2212<\/jats:sup>\n                      CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell compartment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tofacitinib strongly alters T cell responses and potentially limits T cell pathogenicity by decreasing their activation, polyfunctionality, differentiation, and metabolic potential in both the circulation and the joints of patients with inflammatory arthritis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00011-026-02242-5","type":"journal-article","created":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T03:45:36Z","timestamp":1777952736000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["JAK\/STAT inhibition reprograms T cell activation and metabolism in inflammatory arthritis patients"],"prefix":"10.1007","volume":"75","author":[{"given":"Viviana","family":"Marzaioli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aenea A. I.","family":"Brugman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niamh","family":"O\u2019Dowd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilleas","family":"Floudas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aine","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Veale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Fearon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"2242_CR1","doi-asserted-by":"publisher","first-page":"e000656","DOI":"10.1136\/rmdopen-2018-000656","volume":"4","author":"JF Merola","year":"2018","unstructured":"Merola JF, Espinoza LR, Fleischmann R. Distinguishing rheumatoid arthritis from psoriatic arthritis. RMD Open. 2018;4:e000656.","journal-title":"RMD Open"},{"issue":"13 Suppl","key":"2242_CR2","first-page":"S295","volume":"18","author":"MJ Allan Gibofsky","year":"2012","unstructured":"Allan Gibofsky MJ. Overview of epidemiology, pathophysiology, and diagnosis of rheumatoid arthritis. Am J Manag Care. 2012;18(13 Suppl):S295-302.","journal-title":"Am J Manag Care"},{"issue":"1","key":"2242_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1196\/annals.1351.019","volume":"1069","author":"TK Kvien","year":"2006","unstructured":"Kvien TK, Uhlig T, \u00d8deg\u00e5rd S, Heiberg MS. Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci. 2006;1069(1):212\u201322.","journal-title":"Ann N Y Acad Sci"},{"key":"2242_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.2147\/JIR.S219586","volume":"13","author":"R Harrington","year":"2020","unstructured":"Harrington R, Al Nokhatha SA, Conway R. JAK inhibitors in rheumatoid arthritis: an evidence-based review on the emerging clinical data. J Inflamm Res. 2020;13:519.","journal-title":"J Inflamm Res"},{"key":"2242_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-024-03431-5","volume":"26","author":"B D\u2019Onofrio","year":"2024","unstructured":"D\u2019Onofrio B, De Stefano L, Bozzalla Cassione E, Morandi V, Cuzzocrea F, Sakellariou G, et al. Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat. Arthritis Res Ther. 2024;26:1\u20139.","journal-title":"Arthritis Res Ther"},{"key":"2242_CR6","doi-asserted-by":"publisher","first-page":"755844","DOI":"10.3389\/fimmu.2021.755844","volume":"12","author":"Z Wang","year":"2021","unstructured":"Wang Z, Huang J, Xie D, He D, Lu A, Liang C. Toward overcoming treatment failure in rheumatoid arthritis. Front Immunol. 2021;12:755844.","journal-title":"Front Immunol"},{"key":"2242_CR7","doi-asserted-by":"publisher","first-page":"e000308","DOI":"10.1136\/rmdopen-2016-000308","volume":"2","author":"V Strand","year":"2016","unstructured":"Strand V, Lee EB, Fleischmann R, Alten RE, Koncz T, Zwillich SH, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open. 2016;2:e000308.","journal-title":"RMD Open"},{"key":"2242_CR8","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40744-018-0131-5","volume":"5","author":"P Nash","year":"2018","unstructured":"Nash P, Coates LC, Fleischmann R, Papp KA, Gomez-Reino JJ, Kanik KS, et al. Efficacy of tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. Rheumatol Ther. 2018;5:567\u201382.","journal-title":"Rheumatol Ther"},{"key":"2242_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.672461","volume":"12","author":"A O\u2019Brien","year":"2021","unstructured":"O\u2019Brien A, Hanlon MM, Marzaioli V, Wade SC, Flynn K, Fearon U, et al. Targeting JAK-STAT signalling alters PsA synovial fibroblast pro-inflammatory and metabolic function. Front Immunol. 2021;12:2445.","journal-title":"Front Immunol"},{"key":"2242_CR10","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","volume":"75","author":"W Gao","year":"2016","unstructured":"Gao W, McGarry T, Orr C, McCormick J, Veale DJ, Fearon U. Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors. Ann Rheum Dis. 2016;75:311\u20135.","journal-title":"Ann Rheum Dis"},{"key":"2242_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3389\/fimmu.2019.00541","volume":"10","author":"M Diller","year":"2019","unstructured":"Diller M, Hasseli R, H\u00fclser ML, Aykara I, Frommer K, Rehart S, et al. Targeting activated synovial fibroblasts in rheumatoid arthritis by Peficitinib. Front Immunol. 2019;10:541.","journal-title":"Front Immunol"},{"key":"2242_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.00124","volume":"7","author":"B Burja","year":"2020","unstructured":"Burja B, Mertelj T, Frank-Bertoncelj M. Hi-JAKi-ng synovial fibroblasts in inflammatory arthritis with JAK inhibitors. Front Med. 2020;7:124.","journal-title":"Front Med"},{"key":"2242_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar3333","volume":"13","author":"K Migita","year":"2011","unstructured":"Migita K, Komori A, Torigoshi T, Maeda Y, Izumi Y, Jiuchi Y, et al. CP690,550 inhibits oncostatin M-induced JAK\/STAT signaling pathway in rheumatoid synoviocytes. Arthritis Res Ther. 2011;13:1\u201310.","journal-title":"Arthritis Res Ther"},{"key":"2242_CR14","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1136\/annrheumdis-2015-208476","volume":"75","author":"M Biniecka","year":"2016","unstructured":"Biniecka M, Canavan M, McGarry T, Gao W, McCormick J, Cregan S, et al. Dysregulated bioenergetics: a key regulator of joint inflammation. Ann Rheum Dis. 2016;75:2192\u2013200.","journal-title":"Ann Rheum Dis"},{"key":"2242_CR15","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1002\/art.40569","volume":"70","author":"T McGarry","year":"2018","unstructured":"McGarry T, Orr C, Wade S, Biniecka M, Wade S, Gallagher L, et al. JAK \/ STAT blockade alters synovial bioenergetics, mitochondrial function, and proinflammatory mediators in rheumatoid arthritis. Arthritis Rheumatol. 2018;70:1959\u201370.","journal-title":"Arthritis Rheumatol"},{"key":"2242_CR16","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3389\/fimmu.2020.01406","volume":"11","author":"V Marzaioli","year":"2020","unstructured":"Marzaioli V, Canavan M, Floudas A, Wade SC, Low C, Veale DJ, et al. Monocyte-derived dendritic cell differentiation in inflammatory arthritis is regulated by the JAK\/STAT axis via NADPH oxidase regulation. Front Immunol. 2020;11:1406.","journal-title":"Front Immunol"},{"key":"2242_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.722349","volume":"12","author":"V Marzaioli","year":"2022","unstructured":"Marzaioli V, Canavan M, Floudas A, Flynn K, Mullan R, Veale DJ, et al. CD209\/CD14+ dendritic cells characterization in rheumatoid and psoriatic arthritis patients: activation, synovial infiltration, and therapeutic targeting. Front Immunol. 2022;12:5792.","journal-title":"Front Immunol"},{"key":"2242_CR18","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1136\/annrheumdis-2013-203756","volume":"73","author":"S Kubo","year":"2014","unstructured":"Kubo S, Yamaoka K, Kondo M, Yamagata K, Zhao J, Iwata S, et al. The JAK inhibitor, tofacitinib, reduces the T cell stimulatory capacity of human monocyte-derived dendritic cells. Ann Rheum Dis. 2014;73:2192\u20138.","journal-title":"Ann Rheum Dis"},{"key":"2242_CR19","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1093\/rheumatology\/ket466","volume":"53","author":"K Sonomoto","year":"2014","unstructured":"Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, et al. Effects of tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse events. Rheumatology. 2014;53:914\u20138.","journal-title":"Rheumatology"},{"key":"2242_CR20","doi-asserted-by":"publisher","first-page":"e2250353","DOI":"10.1002\/eji.202250353","volume":"53","author":"VA Alamino","year":"2023","unstructured":"Alamino VA, Onofrio LI, del Acosta CV, Ferrero PV, Zacca ER, Cadile II, et al. Tofacitinib treatment of Rheumatoid Arthritis: increases senescent T cell frequency in patients and limits T cell function in vitro. Eur J Immunol. 2023;53:e2250353.","journal-title":"Eur J Immunol"},{"key":"2242_CR21","doi-asserted-by":"publisher","first-page":"2249","DOI":"10.4049\/jimmunol.1600737","volume":"198","author":"SA Basdeo","year":"2017","unstructured":"Basdeo SA, Cluxton D, Sulaimani J, Moran B, Canavan M, Orr C, et al. Ex-Th17 (nonclassical Th1) cells are functionally distinct from classical Th1 and Th17 cells and are not constrained by regulatory T cells. J Immunol. 2017;198:2249\u201359.","journal-title":"J Immunol"},{"key":"2242_CR22","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1002\/art.41150","volume":"72","author":"C Foley","year":"2020","unstructured":"Foley C, Floudas A, Canavan M, Biniecka M, MacDermott EJ, Veale DJ, et al. Increased T cell plasticity with dysregulation of follicular helper T, peripheral helper T, and Treg cell responses in children with juvenile idiopathic arthritis and down syndrome-associated arthritis. Arthritis Rheumatol. 2020;72:677\u201386.","journal-title":"Arthritis Rheumatol"},{"key":"2242_CR23","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1136\/annrheumdis-2018-214138","volume":"78","author":"SM Wade","year":"2019","unstructured":"Wade SM, Canavan M, McGarry T, Low C, Wade SC, Mullan RH, et al. Association of synovial tissue polyfunctional T-cells with DAPSA in psoriatic arthritis. Ann Rheum Dis. 2019;78:350.","journal-title":"Ann Rheum Dis"},{"key":"2242_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells10030647","volume":"10","author":"A Floudas","year":"2021","unstructured":"Floudas A, Canavan M, McGarry T, Mullan R, Nagpal S, Veale DJ, et al. Acpa status correlates with differential immune profile in patients with rheumatoid arthritis. Cells. 2021;10:1\u201315.","journal-title":"Cells"},{"key":"2242_CR25","doi-asserted-by":"publisher","first-page":"830998","DOI":"10.3389\/fmed.2022.830998","volume":"9","author":"A Floudas","year":"2022","unstructured":"Floudas A, Gorman A, Neto N, Monaghan MG, Elliott Z, Fearon U, et al. Inside the joint of inflammatory arthritis patients: handling and processing of synovial tissue biopsies for high throughput analysis. Front Med. 2022;9:830998.","journal-title":"Front Med"},{"key":"2242_CR26","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/annrheumdis-2021-220458","volume":"81","author":"A Floudas","year":"2022","unstructured":"Floudas A, Neto N, Orr C, Canavan M, Gallagher P, Hurson C, et al. Loss of balance between protective and pro-inflammatory synovial tissue T-cell polyfunctionality predates clinical onset of rheumatoid arthritis. Ann Rheum Dis. 2022;81:193\u2013205.","journal-title":"Ann Rheum Dis"},{"key":"2242_CR27","doi-asserted-by":"publisher","first-page":"6894374","DOI":"10.1155\/2017\/6894374","volume":"2017","author":"S Dulic","year":"2017","unstructured":"Dulic S, V\u00e1s\u00e1rhelyi Z, Sava F, Berta L, Szalay B, Toldi G, et al. T-cell subsets in rheumatoid arthritis patients on long-term anti-TNF or IL-6 receptor blocker therapy. Mediators Inflamm. 2017;2017:6894374.","journal-title":"Mediators Inflamm"},{"key":"2242_CR28","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1002\/art.40521","volume":"70","author":"LI Onofrio","year":"2018","unstructured":"Onofrio LI, Zacca ER, Ferrero P, Acosta C, Mussano E, Onetti L, et al. Inhibitory receptor expression on T cells as a marker of disease activity and target to regulate effector cellular responses in rheumatoid arthritis. Arthritis Rheumatol. 2018;70:1429\u201339.","journal-title":"Arthritis Rheumatol"},{"key":"2242_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/ar1192","volume":"6","author":"D Cao","year":"2004","unstructured":"Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstr\u00f6m V. CD25brightCD4+regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther. 2004;6:1\u201312.","journal-title":"Arthritis Res Ther"},{"key":"2242_CR30","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s13075-020-02380-z","volume":"23","author":"K Murray","year":"2021","unstructured":"Murray K, Turk M, Alammari Y, Young F, Gallagher P, Saber T, et al. Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Res Ther. 2021;23:25.","journal-title":"Arthritis Res Ther"},{"key":"2242_CR31","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jid.2020.07.011","volume":"141","author":"FO Novais","year":"2021","unstructured":"Novais FO, Nguyen BT, Scott P. Granzyme B inhibition by tofacitinib blocks the pathology induced by CD8 T cells in cutaneous leishmaniasis. J Invest Dermatol. 2021;141:575\u201385.","journal-title":"J Invest Dermatol"},{"key":"2242_CR32","doi-asserted-by":"publisher","first-page":"9047","DOI":"10.3390\/ijms24109047","volume":"24","author":"JD Vavilova","year":"2023","unstructured":"Vavilova JD, Ustiuzhanina MO, Boyko AA, Streltsova MA, Kust SA, Kanevskiy LM, et al. Alterations in the CD56\u2212 and CD56+ T cell subsets during COVID-19. Int J Mol Sci. 2023;24:9047.","journal-title":"Int J Mol Sci"},{"key":"2242_CR33","doi-asserted-by":"crossref","first-page":"283540","DOI":"10.3389\/fimmu.2017.00892","volume":"8","author":"HH Van Acker","year":"2017","unstructured":"Van Acker HH, Capsomidis A, Smits EL, Van Tendeloo VF. CD56 in the immune system: more than a marker for cytotoxicity? Front Immunol. 2017;8:283540.","journal-title":"Front Immunol"},{"key":"2242_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3324\/haematol.13543","volume":"94","author":"L Fischer","year":"2008","unstructured":"Fischer L, G\u00f6kbuget N, Schwartz S, Burmeister T, Rieder H, Br\u00fcggemann M, et al. CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy. Haematologica. 2008;94:224.","journal-title":"Haematologica"},{"key":"2242_CR35","doi-asserted-by":"publisher","first-page":"ar64","DOI":"10.1091\/mbc.E23-12-0463","volume":"35","author":"AL Martinez","year":"2024","unstructured":"Martinez AL, Shannon MJ, Sloan T, Mace EM. CD56\/NCAM mediates cell migration of human NK cells by promoting integrin-mediated adhesion turnover. Mol Biol Cell. 2024;35:ar64.","journal-title":"Mol Biol Cell"},{"key":"2242_CR36","doi-asserted-by":"publisher","first-page":"153858","DOI":"10.3389\/fimmu.2015.00384","volume":"6","author":"M Mellado","year":"2015","unstructured":"Mellado M, Mart\u00ednez-Mu\u00f1oz L, Cascio G, Lucas P, Pablos JL, Rodr\u00edguez-Frade JM. T cell migration in rheumatoid arthritis. Front Immunol. 2015;6:153858.","journal-title":"Front Immunol"},{"key":"2242_CR37","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/ITT.S243636","volume":"9","author":"NM Elemam","year":"2020","unstructured":"Elemam NM, Hannawi S, Maghazachi AA. Role of chemokines and chemokine receptors in rheumatoid arthritis. ImmunoTargets Ther. 2020;9:43.","journal-title":"ImmunoTargets Ther"},{"key":"2242_CR38","first-page":"117","volume":"19","author":"M Strazza","year":"2015","unstructured":"Strazza M, Azoulay-Alfaguter I, Silverman GJ, Mor A. T Cell chemokine receptor patterns as pathogenic signatures in autoimmunity. Discov Med. 2015;19:117\u201325.","journal-title":"Discov Med"},{"key":"2242_CR39","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1038\/ni1238","volume":"6","author":"GF Debes","year":"2005","unstructured":"Debes GF, Arnold CN, Young AJ, Krautwald S, Lipp M, Hay JB, et al. CC chemokine receptor 7 required for T lymphocyte exit from peripheral tissues. Nat Immunol. 2005;6:889.","journal-title":"Nat Immunol"},{"key":"2242_CR40","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1038\/s42255-025-01331-9","volume":"7","author":"M Certo","year":"2025","unstructured":"Certo M, Pontarini E, Gilbert SG, Schmidt R, Turner JD, Lucchesi D, et al. Lactate signalling leads to aggregation of immune-inflammatory hotspots and SLC5A12 blockade promotes their resolution. Nat Metab. 2025;7:1663\u201380.","journal-title":"Nat Metab"},{"key":"2242_CR41","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1097\/BOR.0000000000000683","volume":"32","author":"CM Weyand","year":"2020","unstructured":"Weyand CM, Wu B, Goronzy JJ. The metabolic signature of T cells in rheumatoid arthritis. Curr Opin Rheumatol. 2020;32:159.","journal-title":"Curr Opin Rheumatol"},{"key":"2242_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1600-065X.2012.01150.x","volume":"249","author":"GJW van der Windt","year":"2012","unstructured":"van der Windt GJW, Pearce EL. Metabolic switching and fuel choice during T-cell differentiation and memory development. Immunol Rev. 2012;249:27\u201342.","journal-title":"Immunol Rev"},{"key":"2242_CR43","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.3389\/fimmu.2019.01743","volume":"10","author":"PG de Oliveira","year":"2019","unstructured":"de Oliveira PG, Farinon M, Sanchez-Lopez E, Miyamoto S, Guma M. Fibroblast-like synoviocytes glucose metabolism as a therapeutic target in rheumatoid arthritis. Front Immunol. 2019;10:1743.","journal-title":"Front Immunol"},{"key":"2242_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1237","volume":"10","author":"T McGarry","year":"2021","unstructured":"McGarry T, Hanlon MM, Marzaioli V, Cunningham CC, Krishna V, Murray K, et al. Rheumatoid arthritis CD14+ monocytes display metabolic and inflammatory dysfunction, a phenotype that precedes clinical manifestation of disease. Clin Transl Immunol. 2021;10:e1237.","journal-title":"Clin Transl Immunol"},{"key":"2242_CR45","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","volume":"75","author":"CG Skorpen","year":"2016","unstructured":"Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis. 2016;75:795\u2013810.","journal-title":"Ann Rheum Dis"},{"key":"2242_CR46","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1080\/14656566.2017.1370453","volume":"18","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R. A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate. Expert Opin Pharmacother. 2017;18:1525\u201333. https:\/\/doi.org\/10.1080\/14656566.2017.1370453.","journal-title":"Expert Opin Pharmacother"},{"key":"2242_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01406","volume":"11","author":"V Marzaioli","year":"2020","unstructured":"Marzaioli V, Canavan M, Floudas A, Wade SC, Low C, Veale DJ, et al. Monocyte-derived dendritic cell differentiation in inflammatory arthritis is regulated by the JAK\/STAT Axis via NADPH oxidase regulation. Front Immunol. 2020;11:1406. https:\/\/doi.org\/10.3389\/fimmu.2020.01406.","journal-title":"Front Immunol"},{"key":"2242_CR48","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5021537","volume":"2016","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Leng X, Luo S, Su Z, Luo X, Guo H, et al. Tolerogenic dendritic cells generated with tofacitinib ameliorate experimental autoimmune encephalomyelitis through modulation of Th17\/Treg balance. J Immunol Res. 2016;2016:5021537. https:\/\/doi.org\/10.1155\/2016\/5021537.","journal-title":"J Immunol Res"},{"key":"2242_CR49","doi-asserted-by":"publisher","first-page":"e238851","DOI":"10.1136\/bcr-2020-238851","volume":"14","author":"K Murray","year":"2021","unstructured":"Murray K, Floudas A, Murray C, Fabre A, Crown J, Fearon U, et al. First use of tofacitinib to treat an immune checkpoint inhibitor-induced arthritis. BMJ Case Rep. 2021;14:e238851.","journal-title":"BMJ Case Rep"},{"key":"2242_CR50","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1002\/art.40780","volume":"71","author":"R van Vollenhoven","year":"2019","unstructured":"van Vollenhoven R, Lee EB, Strengholt S, Mojcik C, Valdez H, Krishnaswami S, et al. Evaluation of the short-, mid-, and long-term effects of tofacitinib on lymphocytes in patients with rheumatoid arthritis. Arthritis Rheumatol. 2019;71:685\u201395.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"2242_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13075-021-02509-8","volume":"23","author":"HC Hawerkamp","year":"2021","unstructured":"Hawerkamp HC, Domdey A, Radau L, Sewerin P, Ol\u00e1h P, Homey B, et al. Tofacitinib downregulates antiviral immune defence in keratinocytes and reduces T cell activation. Arthritis Res Ther. 2021;23(1):1\u201312. https:\/\/doi.org\/10.1186\/s13075-021-02509-8.","journal-title":"Arthritis Res Ther"},{"key":"2242_CR52","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/art.42960","volume":"76","author":"F Beck","year":"2024","unstructured":"Beck F, Nguyen P, Hoffmann A, Loyal L, Thiel A, Melzer M, et al. CD4 + CD8\u03b1 low T cell clonal expansion dependent on costimulation in patients with rheumatoid arthritis. Arthritis Rheumatol. 2024;76:1719.","journal-title":"Arthritis Rheumatol"},{"key":"2242_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s11926-025-01180-1","volume":"27","author":"A Chin","year":"2025","unstructured":"Chin A, Small A, Wong SW, Wechalekar MD. T cell dysregulation in rheumatoid arthritis: from genetic susceptibility to established disease. Curr Rheumatol Rep. 2025;27:14.","journal-title":"Curr Rheumatol Rep"},{"key":"2242_CR54","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1136\/annrheumdis-2021-221761","volume":"81","author":"A Floudas","year":"2022","unstructured":"Floudas A, Smith CM, Tynan O, Neto N, Krishna V, Wade SM, et al. Distinct stromal and immune cell interactions shape the pathogenesis of rheumatoid and psoriatic arthritis. Ann Rheum Dis. 2022;81:1224\u201342.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2242_CR55","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s10165-012-0799-2","volume":"23","author":"Y Tanaka","year":"2012","unstructured":"Tanaka Y, Yamaoka K. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical. Mod Rheumatol. 2012;23(3):415\u201324. https:\/\/doi.org\/10.1007\/s10165-012-0799-2.","journal-title":"Mod Rheumatol"},{"key":"2242_CR56","first-page":"1313","volume":"40","author":"M Bedaj","year":"2022","unstructured":"Bedaj M, Bonilha CS, McInnes IB, Garside P, Benson RA. Tofacitinib inhibits CD4 T cell polarisation to Th1 during priming thereby leading to clinical impact in a model of experimental arthritis. Clin Exp Rheumatol. 2022;40:1313\u201323.","journal-title":"Clin Exp Rheumatol"},{"key":"2242_CR57","doi-asserted-by":"publisher","first-page":"539683","DOI":"10.1155\/2012\/539683","volume":"2012","author":"S Maeda","year":"2012","unstructured":"Maeda S, Hayami Y, Naniwa T, Ueda R. The Th17\/IL-23 axis and natural immunity in psoriatic arthritis. Int J Rheumatol. 2012;2012:539683.","journal-title":"Int J Rheumatol"},{"key":"2242_CR58","doi-asserted-by":"publisher","first-page":"535361","DOI":"10.1155\/2012\/535361","volume":"2012","author":"J Chen","year":"2012","unstructured":"Chen J, Li J, Gao H, Wang C, Luo J, Lv Z, et al. Comprehensive evaluation of different T-helper cell subsets differentiation and function in rheumatoid arthritis. J Biomed Biotechnol. 2012;2012:535361.","journal-title":"J Biomed Biotechnol"},{"key":"2242_CR59","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1302\/2046-3758.117.BJR-2021-0594.R1","volume":"11","author":"P Luo","year":"2022","unstructured":"Luo P, Wang P, Xu J, Hou W, Xu P, Xu K, et al. Immunomodulatory role of T helper cells in rheumatoid arthritis: a comprehensive research review. Bone Joint Res. 2022;11:426.","journal-title":"Bone Joint Res"},{"key":"2242_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1245535","volume":"14","author":"D Collotta","year":"2023","unstructured":"Collotta D, Franchina MP, Carlucci V, Collino M. Recent advances in JAK inhibitors for the treatment of metabolic syndrome. Front Pharmacol. 2023;14:1245535.","journal-title":"Front Pharmacol"},{"key":"2242_CR61","doi-asserted-by":"publisher","first-page":"12571","DOI":"10.3390\/ijms241612571","volume":"24","author":"MP Adorni","year":"2023","unstructured":"Adorni MP, Papotti B, Borghi MO, Raschi E, Zimetti F, Bernini F, et al. Effect of the JAK\/STAT inhibitor tofacitinib on macrophage cholesterol metabolism. Int J Mol Sci. 2023;24:12571.","journal-title":"Int J Mol Sci"},{"key":"2242_CR62","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/eji.202049159","volume":"51","author":"K Palasiewicz","year":"2021","unstructured":"Palasiewicz K, Umar S, Romay B, Zomorrodi RK, Shahrara S. Tofacitinib therapy intercepts macrophage metabolic reprogramming instigated by SARS-CoV-2 Spike protein. Eur J Immunol. 2021;51:2330.","journal-title":"Eur J Immunol"},{"key":"2242_CR63","doi-asserted-by":"publisher","first-page":"738481","DOI":"10.3389\/fimmu.2021.738481","volume":"12","author":"M Palmroth","year":"2021","unstructured":"Palmroth M, Kuuliala K, Peltomaa R, Virtanen A, Kuuliala A, Kurttila A, et al. Tofacitinib suppresses several JAK-STAT pathways in rheumatoid arthritis in vivo and baseline signaling profile associates with treatment response. Front Immunol. 2021;12:738481.","journal-title":"Front Immunol"},{"key":"2242_CR64","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.4049\/jimmunol.1003668","volume":"186","author":"K Ghoreschi","year":"2011","unstructured":"Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, et al. Modulation of innate and adaptive immune responses by Tofacitinib (CP-690,550). J Immunol. 2011;186:4234\u201343.","journal-title":"J Immunol"}],"container-title":["Inflammation Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02242-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00011-026-02242-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00011-026-02242-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T17:04:41Z","timestamp":1778000681000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00011-026-02242-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2242"],"URL":"https:\/\/doi.org\/10.1007\/s00011-026-02242-5","relation":{},"ISSN":["1420-908X"],"issn-type":[{"value":"1420-908X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]},"assertion":[{"value":"6 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"108"}}